CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Scienture Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Scienture Holdings Inc
2420 Brunello Trace
Phone: (813) 601-3533p:813 601-3533 LUTZ, FL  33558  United States Ticker: SCNXSCNX
Business Summary
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
1000 Metal mining
5122 Drugs, drug proprietaries, and druggists' sundries
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Secretary SurendraAjjarapu 53 1/8/2014 1/8/2014
President, Chief Operating Officer PrashantPatel 50 1/13/2025 1/8/2014
Chief Financial Officer EricSherb 38 3/13/2025 3/13/2025
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Integra Pharma Solutions, LLC. 6308 Benjamin Rd Tampa FL United States

Business Names
Business Name
Alliance Pharma Solutions, LLC,
Bluebird Exploration Company
Bonum Health, Inc a Delaware corporation.
7 additional Business Names available in full report.

General Information
Number of Employees: 14 (As of 12/31/2024)
Outstanding Shares: 12,515,019 (As of 3/26/2025)
Shareholders: 90
Stock Exchange: NASD
Fax Number: (800) 253-5177
Email Address: ir@xcellink.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025